MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

347

Participants

Timeline

Start Date

September 28, 2012

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Asthma
Interventions
DRUG

Mepolizumab

100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks

Trial Locations (64)

2305

GSK Investigational Site, New Lambton

3004

GSK Investigational Site, Melbourne

3168

GSK Investigational Site, Clayton

5000

GSK Investigational Site, Adelaide

6009

GSK Investigational Site, Nedlands

10367

GSK Investigational Site, Berlin

10717

GSK Investigational Site, Berlin

13915

GSK Investigational Site, Marseille

15213

GSK Investigational Site, Pittsburgh

15562

GSK Investigational Site, Rüdersdorf

17033

GSK Investigational Site, Hershey

23552

GSK Investigational Site, Lübeck

27103

GSK Investigational Site, Winston-Salem

31707

GSK Investigational Site, Albany

34295

GSK Investigational Site, Montpellier

37212

GSK Investigational Site, Nashville

39120

GSK Investigational Site, Magdeburg

40508

GSK Investigational Site, Lexington

44195

GSK Investigational Site, Cleveland

49051

GSK Investigational Site, Dnipropetrovsk

55131

GSK Investigational Site, Mainz

60596

GSK Investigational Site, Frankfurt am Main

61035

GSK Investigational Site, Kharkiv

80206

GSK Investigational Site, Denver

83099

GSK Investigational Site, Donetsk

90808

GSK Investigational Site, Long Beach

92506

GSK Investigational Site, Riverside

94275

GSK Investigational Site, Le Kremlin-Bicêtre

97448

GSK Investigational Site, Saint-Pierre

123182

GSK Investigational Site, Moscow

191015

GSK Investigational Site, St'Petersburg

194354

GSK Investigational Site, Saint Petersburg

420008

GSK Investigational Site, Kazan'

454106

GSK Investigational Site, Chelyabinsk

540143

GSK Investigational Site, Târgu Mureş

700115

GSK Investigational Site, Iași

2341131

GSK Investigational Site, Valparaíso

4270918

GSK Investigational Site, Talcahuano

8207257

GSK Investigational Site, Puente Alto - Santiago

8380453

GSK Investigational Site, Santiago

06520

GSK Investigational Site, New Haven

B7600FZN

GSK Investigational Site, Mar del Plata

C1121ABE

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

T2N 4Z6

GSK Investigational Site, Calgary

V5Z 1M9

GSK Investigational Site, Vancouver

L5A 3V4

GSK Investigational Site, Mississauga

G1V 4G5

GSK Investigational Site, Québec

90-153

GSK Investigational Site, Lodz

54-239

GSK Investigational Site, Wroclaw

011461

GSK Investigational Site, Bucharest

050159

GSK Investigational Site, Bucharest

656 045

GSK Investigational Site, Barnaul

105 077

GSK Investigational Site, Moscow

361-711

GSK Investigational Site, Cheongju, Chungcheongbuk-do

443-721

GSK Investigational Site, Suwon, Kyonggi-do

03680

GSK Investigational Site, Kiev

03038

GSK Investigational Site, Kyiv

LE3 9QP

GSK Investigational Site, Leicester

EC1M 6BQ

GSK Investigational Site, London

SW3 6HP

GSK Investigational Site, London

M23 9LT

GSK Investigational Site, Manchester

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01691859 - MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects | Biotech Hunter | Biotech Hunter